Search company, investor...


Founded Year




Market Cap


Stock Price


About LabCorp

LabCorp (NYSE: LH) provides medical laboratory tests and services through a national network of primary clinical laboratories. It caters its services to physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. The firm was founded in 1995 and is based in Burlington, North Carolina.

Headquarters Location

531 South Spring Street

Burlington, North Carolina, 27215,

United States


Missing: LabCorp's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LabCorp's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing LabCorp

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned LabCorp in 3 CB Insights research briefs, most recently on Oct 28, 2022.

Expert Collections containing LabCorp

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LabCorp is included in 4 Expert Collections, including Fortune 500 Investor list.


Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.


Conference Exhibitors

5,302 items


Medical Devices

3,160 items


Health Monitoring & Diagnostics

282 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

Latest LabCorp News

The Global Large Molecule Bioanalytical Testing Services Market size is expected to reach $2.8 billion by 2028, rising at a market growth of 9.1% CAGR during the forecast period

Nov 23, 2022

Lyon, FRANCE New York, Nov. 23, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Global Large Molecule Bioanalytical Testing Services Market Size, Share & Industry Trends Analysis Report By End-user, By Test Type, By Type, By Phase, By Therapeutic Areas, By Regional Outlook and Forecast, 2022 - 2028" - Large molecule bioanalysis by CROs like PBL has increased in popularity as more & more large molecule products are being developed. Pharmacokinetic (PK) studies, immunogenicity testing, pharmacodynamics (PD) studies, and biomarker assays are the most typical types of bioanalytical studies. The demand for high-tech and dependable large molecule bioanalytical testing services is one of many factors contributing to the industry’s expected growth. Additionally, the demand for analytical testing services has increased due to the complexity of product designs and engineering. To keep up with market demand, pharmaceutical companies now face a greater requirement than ever to implement innovative technology in their services. The development of bioanalytical assays aids in identifying the design considerations, constraints, favorable circumstances, and applicability of a medicine for the intended treatment. The information on protein binding and in vivo/in vitro metabolism, combined with important facets of earlier work on the method, greatly influences the creation of bioanalytical assays. Given their capacity to ascertain the purity, identification, performance, and potency of these compounds, bioanalytical tests play a significant role in the discovery & development of pharmaceutical products. Additionally, the methodologies used enable the quantification of analytes in a variety of biological matrices, including plasma, blood, urine, or serum. COVID-19 Impact Analysis Reduced internal lab testing capacities at several biopharmaceutical companies led to a rise in CRO workload, the suspension of courier services, and initial IT problems, among other first interruptions. The market experienced a little positive growth in 2020, and it is projected that this trend will continue during the projection period. Following the pandemic, the industry experienced steady growth as a result of factors like the acceleration of COVID-19 vaccine R&D and the rise in agreements and partnerships between CROs and biopharmaceutical businesses to outsource their bioanalytical testing needs. Because healthcare costs are rising, there is a growing demand for high-quality care. Market Growth Factors Increasing attention on biologics and biosimilars’ analytical testing In the pharmaceutical industry, biologics are one of the most significant and latest therapeutic areas, and there are currently a large number of products in the pipeline. The increasing prevalence of chronic diseases is one of the main causes of this. However, the emphasis on biosimilars has grown in recent years due to the high cost of biologics and the growing focus of various governments on cutting healthcare costs. The development of follow-on biologics or biosimilars has also been made possible by the approaching expiration of biologics’ patents and exclusivity periods. As a result, the market for large molecule bioanalytical testing services would expand at a significant rate. Rising preference to outsource analytical testing Pharmaceutical firms have started outsourcing a number of R&D tasks that are not essential to their internal operations. Companies are attempting to develop drugs more effectively by concentrating on their internal core competencies in order to introduce new goods to the market more affordably. For major businesses, outsourcing bioanalytical testing has a number of benefits, including lower costs, increased productivity, and the best manpower. Therefore, the large molecule bioanalytical testing services market is expanding. Market Restraining Factors Growing demand for bioanalytical procedures to be made more sensitive Making sure that procedures are sufficiently sensitive, quick to analyze, and robust is one of the major issues in this field. It is quite challenging for service providers to guarantee adequate testing capabilities due to fluctuations, changes, and variations in end-user demands & regulatory requirements; they must constantly search out and apply novel and fresh assays. For instance, to evaluate low CZP concentrations in newborn and umbilical cord blood, extremely sensitive and selective bioanalytical tests are needed to assess the placental transfer of certolizumab pegol (CZP). Phase Outlook Based on phase, the large molecule bioanalytical testing services market is segmented into preclinical (with antibody, without antibody), and clinical. The preclinical segment acquired a substantial revenue share in the large molecule bioanalytical testing services market in 2021. Preclinical segment includes pharmacokinetic bioanalysis of plasma or serum samples. In this stud, the drug product is administered to humans or animals, and blood samples are subsequently taken at various intervals. The serum or plasma is separated & sent to a lab for examination. The lab carries out two different kinds of preclinical studies (in vivo and in vitro). Type Outlook On the basis of type, the large molecule bioanalytical testing services market is fragmented into pharmacokinetics, ADA and others. In 2021, the ADA segment held the largest revenue share in the large molecule bioanalytical testing services market. Large molecule drug development is supported by the ADA assays. Antibodies are produced by the immune system in response to large molecular medications like antibodies and protein therapies. As a result, ADA assays can be used to detect ADAs. Owing to this, the demand for ADA is estimated to rise in the upcoming years supporting the market growth. Test Type Outlook By test Type, the large molecule bioanalytical testing services market is classified into ADME, PD, bioavailability, bioequivalence and other tests. In 2021, the PD segment generated a substantial revenue share in the large molecule bioanalytical testing services market in 2021. Pharmacodynamic (PD) studies examine how the medication affects the patient, including its biochemical and physiological effects. The drug’s mechanism of action, or how it functions on a biochemical level, can be better understood through pharmacodynamic big molecule bioanalysis. Therapeutic Areas Outlook Based on therapeutic areas, the large molecule bioanalytical testing services market is bifurcated into oncology, infectious diseases, cardiology, neurology and others. In 2021, the oncology segment accounted the maximum revenue share in the large molecule bioanalytical testing services market. The World Health Organization estimates that in year 2020, cancer was one of the top reasons of mortality worldwide, accounting for over 10 million fatalities. Some of the major drivers that are anticipated to propel the segment’s growth include an increase in cancer incidence, a fast-growing senior population, and an unhealthy lifestyle. End-user Outlook On the basis of end-user, the large molecule bioanalytical testing services market is divided into SMEs (CROs & CMOs, sponsor Organizations, others) and large firms (CROs & CMOs, sponsor organizations, and others). In 2021, the SMEs segment registered the largest revenue share in the large molecule bioanalytical testing services market. This is because of the increasing innovations by the small-scale pharmaceutical companies. Further, the market is expanding in this segment due to the increased number of small local market players providing large molecule bioanalytical testing services in the upcoming years. Regional Outlook Region wise, the large molecule bioanalytical testing services market is analyzed across the North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the large molecule bioanalytical testing services market by generating maximum revenue share. One of the top manufacturing regions for highly dependable, intricate, and expensive medications is North America. The regional market is expanding as a result of rising investments from companies that provide bioanalytical testing services, rising R&D expenditures in the biopharmaceutical industry, and favorable regulatory reforms. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc. Strategies deployed in Large Molecule Bioanalytical Testing Services Market Oct-2022: IQVIA unveiled the first self-collection safety lab panel for U.S. clinical trial participants. The safety lab panel would be designed in collaboration with Tasso, a leader in clinical-grade blood collection solutions. The launch offers combined industry-leading laboratory services, patient-focused logistics & cutting-edge, self-collection technology. Oct-2022: IQVIA expanded its geographical footprint in North Carolina by opening a new Q² Solutions innovation laboratory. The latest laboratory has an innovative suite of laboratory capabilities, that includes cutting-edge bioanalytical, vaccine, biomarker, and genomics laboratories. Nov-2021: Labcorp expanded its geographical footprints in the Asia-Pacific region by opening the latest integrated bioanalytical laboratory in Singapore. This expansion focused on advancing Labcorp’s position as a life science leader in the APAC region and the whole world. This new laboratory offers customers faster turnaround times for data in early phase trials in the Asia Pacific region. Sep-2021: SGS SA expanded its geographical footprint in France by opening a new facility in Poitiers, France. This expansion would help SGS SA to fulfill the rising demand for bioanalytical testing services to support drug development of small molecules, peptides, biotherapeutics, and cell and gene therapies. Mar-2021: Charles River Laboratories acquired Retrogenix Limited, an early-stage contract research organization. The acquisition would advance Charles River’s scientific expertise within the additional large molecule and cell therapy discovery capabilities. In addition, by combining distributed Bio’s large-molecule discovery platform, Retrogenix’s capabilities would strengthen the company’s end-to-end solution for therapeutic antibody and cell & gene therapy discovery as well as development. Feb-2021: ICON took over PRA Health Sciences, a contract research organization. This acquisition focused on expanding the geographical reach of the services provided by ICON along with a better understanding of drug therapies & wider expertise in healthcare technology innovation. Further, through this acquisition ICON would have both mobiles as well as connected health platforms with real-world data & information solutions. Jan-2021: Charles River Laboratories took over Distributed Bio, a computational immune engineering biotechnology group. This acquisition aimed at expanding Charles River’s scientific capabilities via an innovative, large-molecule discovery platform. The transaction combined Distributed Bio’s antibody libraries & immuno-engineering platform with Charles River’s extensive drug discovery & non-clinical development expertise with an aim to form an integrated, end-to-end platform for therapeutic antibody and cell & gene therapy discovery and development. Feb-2019: ICON completed the acquisition of MolecularMD Corporation, a molecular diagnostic specialty laboratory. This acquisition aimed at expanding ICON’s capabilities in molecular diagnostic testing with the help of MolecularMD’s extensive scientific & clinical biomarker experience. Also, the acquisition would add expanded testing platforms, that include next-generation sequencing & immunohistochemistry, to ICON’s laboratory service offering. Aug-2018: Charles River Laboratories took over MPI Research, a premier non-clinical contract research organization. This acquisition would strengthen Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with customers in the drug discovery and development continuum. Scope of the Study

LabCorp Frequently Asked Questions (FAQ)

  • When was LabCorp founded?

    LabCorp was founded in 1995.

  • Where is LabCorp's headquarters?

    LabCorp's headquarters is located at 531 South Spring Street, Burlington.

  • What is LabCorp's latest funding round?

    LabCorp's latest funding round is PIPE.

  • Who are the investors of LabCorp?

    Investors of LabCorp include Jana Partners.

  • Who are LabCorp's competitors?

    Competitors of LabCorp include LetsGetChecked, Cyted, Scanwell Health, Cue Health, ObvioHealth and 8 more.

Compare LabCorp to Competitors

LetsGetChecked Logo

LetsGetChecked offers at-home tests for a variety of conditions. The company builds and delivers at-home testing kits, including hormone tests, fertility tests, HPV tests and wellness tests for cholesterol or diabetes. Its services includes manufacturing, logistics, lab analysis, clinician support, and prescription fulfillment. The company was founded in 2015 and is based in Dublin, Ireland.

Quest Diagnostics Logo
Quest Diagnostics

Quest Diagnostics offers medical diagnostic testing and services throughout the United States. The company was founded in 1967 and is based in Secaucus, New Jersey.

Everly Health Logo
Everly Health

Everly Health provides an e-commerce platform that enables customers to buy a variety of test kits online, collect their sample at home, and get informative results without visiting a lab or doctor's office. The platform offers various at-home lab tests including sexual health, thyroid, metabolism, men's health, and breast milk DHA testing, which the company is the exclusive provider of in the U.S. It was formerly known as Everlywell.

Weavr Health Logo
Weavr Health

Weavr Health is dedicated to connecting people to health by simplifying sample collection and processing for healthcare.The Velvet device is designed so anyone, anywhere can easily collect high-quality samples without a phlebotomist. The Velvet device offers a smooth experience of blood self-collection for patients. It leverages a similar experience to traditional glucose testing, which >25% of people have experienced. Each device arrives with all that is needed to collect, package and ship quality samples to the lab for a convenient experience.

Sight Diagnostics

Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.


Accellix develops fully automated, cost-effective, actionable cell-based analysis, 24/7 at the point of need, to a broad range of users. Its Accellix single-use cartridge analysis system provides results in less than 30 minutes, requires minimal training, and does not require users to deal with biological reagents, sample preparation, and complex data analysis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.